Trial Radar IA

Discutiamo ed esploriamo gli studi clinici con Halozyme Therapeutics come promotore principale o collaboratore.

Mostrando gli studi clinici che corrispondono al luogo: Texas.

Posso aiutarti a capire le condizioni di salute, i trattamenti o a trovare studi clinici vicini.
Il nostro strumento di ricerca supporta solo l'inglese. Per la ricerca e la discussione in altre lingue, usa Trial Radar IA sopra o seleziona i filtri per condizione medica e luogo (qui sotto).
16 studi clinici
 
Luogo
Texas
×
 
Titolo dello studio
Stato
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism NCT06689085
In arruolamento
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) NCT03281369
Completato
Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma NCT03267940
TerminatoRisultati pubblicati
A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma NCT02715804
TerminatoRisultati pubblicati
A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors NCT02563548
CompletatoRisultati pubblicati
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM) NCT01848990
CompletatoRisultati pubblicati
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer NCT01839487
CompletatoRisultati pubblicati
Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers NCT01572012
Completato
A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase NCT01426763
CompletatoRisultati pubblicati
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus NCT01194258
CompletatoRisultati pubblicati
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus NCT01194245
CompletatoRisultati pubblicati
Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus NCT00883558
CompletatoRisultati pubblicati
Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone NCT00807963
Completato
Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20 NCT00803972
Completato
Subcutaneous Rehydration Compared to Intravenous Rehydration (PEDs-II) NCT00773175
CompletatoRisultati pubblicati
Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20 NCT00705536
CompletatoRisultati pubblicati